Atossa Therapeutics (ATOS) said Wednesday it has completed enrollment in part B of its phase 1/2a trial of drug candidate AT-H201 in Australia. AT-H201 is being developed as an inhalation therapy for moderately to severely ill hospitalized COVID-19 patients and for "long-haul" patients with post-infection pulmonary disease, the clinical-stage drugmaker said. The...
New York Community Bancorp, Inc. is a bank holding company, which engages in the provision of multi-family loans on non-luxury rent-regulated buildings that feature below-market rents. It also offers financial products and services to individuals and businesses. The company was founded on July 20, 1993, and is headquartered in Westbury, NY.
GBS (GBS) on Friday filed a shelf registration statement for the potential sale of up to $100 million of its securities from time to time. The filing covers the sale of the company's common stock, preferred stock, debt securities, warrants, and units. The company expects to use the net proceeds from the sale of securities for its clinical trials and preclinical...
VALU announces its quarterly result, wherein the company posted loss before other item at CAD 0.368 million, higher than CAD 0.210 million in the previous corresponding period (pcp). The quarter witnessed higher Consulting fees (CAD 0.150 million v/s CAD 0.127 million in pcp), an increase in professional fees (CAD 0.034 million v/s CAD 0.021 million in pcp)...
Hardwoods Distribution, Inc. engages in the sourcing and distribution of architectural grade building products to the residential and commercial construction sectors. The firm's products include hardwood lumber, decorative surfaces and composite panels. It operates through the following geographical segments: Canada and United States. The company was founded on...
Despite the consequences of persisting COVID limitations, supply chain constraints, and other challenges that the worldwide sector is now suffering, the firm produced record annual sales in FY2021. The acquisition of Stako significantly boosted the company's 2021 performance and, more crucially, increased its product line and production capabilities. A crucial...
12:00Mar 22, 2021Reuters Sundial Growers Inc Says May Offer And Sell Common Shares Having Offering Price Of Up To US$800 Million From Time To Time SNDL 0.82009.92% Sundial Growers Inc (SNDL): SUNDIAL GROWERS INC - MAY OFFER AND SELL COMMON SHARES HAVING AGGREGATE OFFERING PRICE OF UP TO US$800 MILLION FROM TIME TO TIME THROUGH AGENTS Source text - bit.ly
TD Holdings, Inc. is a holding company, which engages in commodities trading and supply chain service businesses. Its Commodities Trading business is involved in purchasing non-ferrous metal product from metal and mineral suppliers. Its Supply Chain Service business provides commodity supply chain service and digital intelligence supply chain platform integrating...
Progenity, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. Its products include Preparent Carrier Test, Innatal Prenatal Screen, Riscover Hereditary Cancer Test, and Resura Prenatal Test. The company was founded by Paul W. Hawran and Harry Stylli in 2010 and is headquartered in San Diego, CA.
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS™. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer...
Next Target is GOing to be 3.86 - 5.25 Reliance Global Group, Inc. (NASDAQ: RELI, RELIW) is combining advanced technologies, with the personalized experience of a traditional insurance agency model. Reliance Global Group’s growth strategy includes both an organic expansion, including 5MinuteInsure.com, as well as acquiring well managed, undervalued and cash...
Sector: Technology Services Industry: Internet Software/Services Zhangmen Education, Inc. is an online education company that engages in the provision of personalized online courses to K-12 students. Its core course offerings encompass one-on-one and small-class after-school tutoring services covering all core K-12 academic subjects. The company was founded by Yi...
Cryptocurrency-focused Galaxy Digital Holdings Ltd. (GLXY) on Thursday announced that its affiliate, Galaxy Digital Asset Management, reported preliminary assets under management of $2,130.8 million as of August 31, 2021. Target 1 : 31 Target 2 : 36 Target 3 : 46
Support *1 - CAD 1.78 Support *2 - CAD 1. 68 Resistance *1 - CAD 2.46 Resistance *2 - CAD 2.59 **Disclaimer - not financial advice, please trade with caution and DYOR. This prediction Based on My Dreams. I am new to this trade and would appreciate your feedback on my analysis.
Progenity (PROG) said Tuesday the US Patent and Trademark Office has issued a patent for assessment of preeclampsia using assays for free and dissociated placental growth factor, or PIGF. The biotechnology company's chief scientific officer, Matthew Cooper, said the patent protection is important as the company pursues partnership opportunities to commercialize...
Voyager Therapeutics (VYGR) has signed an agreement through which Pfizer Inc. (PFE) may exercise options to license novel capsids generated from Voyager's TRACER screening technology to treat certain neurologic and cardiovascular diseases. Under terms of the deal, Pfizer will have the right to evaluate novel capsids selected for central nervous system and cardiac...
Support *1 - USD 3.79 Support *2 - USD 3.40 Resistance *1 - USD 4.35 Resistance *2 - USD 5.22 **Disclaimer - not financial advice, please trade with caution and DYOR. This prediction Based on My Dreams. I am new to this trade and would appreciate your feedback on my analysis.
Eyegate Pharmaceuticals (EYEG) said Wednesday it has completed its target enrollment of 21 patients in a mid-stage proof-of-concept study of PP-001 for ocular surface inflammation due to ocular surface diseases, including dry eye. Topline data from the study are expected to be released in Q4, with an investigational new drug filing in the same quarter. Target : $ 2.9